title: Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.
abstract: BACKGROUND
  Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common treatable acquired chronic polyneuropathy. Corticosteroids, plasmapheresis and intravenous immunoglobulins (IVIG) have been shown to be effective in randomized controlled clinical trials and IVIG is widely used as a first-line initial and maintenance treatment for CIDP. Studies in animal models of autoimmune diseases indicated that the inhibitory Fc-gamma receptor FcgammaRIIB, expressed on myeloid cells and B cells, is required for the anti-inflammatory activity of IVIG.
  
  
  CONCLUSIONS
  We found that untreated patients with CIDP, compared to demographically matched healthy controls, show lower FcgammaRIIB expression levels on naïve B cells and fail to upregulate or to maintain upregulation of FcgammaRIIB as B cells progress from the naive to the memory compartment. Furthermore, FcgammaRIIB protein expression is upregulated on B cells and monocytes following clinically effective IVIG therapy suggesting that impaired expression of the inhibitory FcgammaR in CIDP can, at least partially, be restored by IVIG treatment. In B cells, FcgammaRIIB transduces an inhibitory signal upon colligation with the B cell receptor, thereby preventing B cells with low affinity or self-reactive receptors from entering the germinal center and becoming IgG positive plasma cells. Our data suggest that this late B cell differentiation checkpoint is impaired in CIDP. Modulating FcgammaRIIB function might be a promising approach to efficiently limit antibody-mediated immunopathology in CIDP.
authors.affiliation: Clinical Neuroimmunology Group, Department of Neurology, Philipps-University, Rudolf-Bultmann-Str. 8, Marburg, Germany.
authors.forename: Björn
authors.initials: B
authors.lastname: Tackenberg
authors.forename: Falk
authors.initials: F
authors.lastname: Nimmerjahn
authors.forename: Jan D
authors.initials: JD
authors.lastname: Lünemann
mesh_terms: D000328:Adult; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D016175:B-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism; D018858:Germinal Center / Q000276:immunology / Q000473:pathology; D006031:Glycosylation; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D007156:Immunologic Memory / Q000187:drug effects; D007249:Inflammation / Q000628:therapy; D038041:Lymphopoiesis / Q000187:drug effects / Q000276:immunology; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology / Q000378:metabolism; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000276:immunology / Q000628:therapy*; D011499:Protein Processing, Post-Translational; D016032:Randomized Controlled Trials as Topic; D017452:Receptors, IgG / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D016896:Treatment Outcome
chemical_list: C499173:FCGR2B protein, human; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D017452:Receptors, IgG